home / stock / skye / skye news

SKYE News and Press, Skye Bioscience Inc Com From 06/07/22

Stock Information
Company Name: Skye Bioscience Inc Com
Stock Symbol: SKYE
Market: NASDAQ
Website: skyebioscience.com
Menu
SKYE SKYE Quote SKYE Short SKYE News SKYE Articles SKYE Message Board
Get SKYE Alerts

News, Short Squeeze, Breakout and More Instantly...
SKYE - Skye Bioscience Expands Cannabinoid Pharmaceutical Innovation Program with Leading Cannabinoid Medicinal Chemistry Groups

New collaborations focused on building library of novel cannabinoid derivatives and small molecules capable of modulating endocannabinoid system San Diego, California, June 07, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company ...
SKYE - Skye Bioscience to Present at LD Micro Invitational

San Diego, California--(Newsfile Corp. - June 6, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing proprietary, synthetic cannabinoid derivatives to treat glaucoma and other diseases with significant unmet need, announced today that it w...

SKYE - Skye Bioscience Reports Enhanced Intraocular Pressure-Lowering of SBI-100 Formulation Published in Peer-Reviewed Journal

San Diego, California, May 05, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid derivatives to treat glaucoma and other diseases with significant unmet n...

SKYE - Skye Bioscience Engages Clinical Trial Site for Phase 1 Study in Agreement with CMAX Clinical Research

San Diego, California, April 28, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid derivatives to treat glaucoma and other diseases with significant unmet...
SKYE - Skye Bioscience Retains Novotech as CRO for Phase 1 Trial of Glaucoma Drug Candidate

San Diego, Calif, March 03, 2022 (GLOBE NEWSWIRE) --  Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with signifi...

SKYE - Skye Bioscience Reports Positive Results for SBI-100 in GLP Toxicology Study

Initiation of Phase 1 clinical trial of SBI-100 o phthalmic nanoemulsion expected in the second quarter of 2022 SAN DIEGO, CA, Feb. 16, 2022 (GLOBE NEWSWIRE) --  Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”...

SKYE - Skye Bioscience Reports Potential Neuroprotective Benefit of SBI-100 In Preclinical Glaucoma Model

SAN DIEGO, CA, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet ne...
SKYE - Skye Bioscience Issues Shareholder Letter Providing Progress Update and Business Outlook for 2022

SAN DIEGO, CA, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a pharmaceutical company developing proprietary, synthetic, cannabinoid-derived molecules to treat diseases with significant unmet need, issued today the following letter from Chief ...

SKYE - Skye Bioscience to Present at H.C. Wainwright BIOCONNECT Virtual Conference

SAN DIEGO, CA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic, cannabinoid-derived molecules to treat diseases with significant unmet need, announced today that it will present a cor...

SKYE - Skye Bioscience Expands Board of Directors with the Appointment of Life Sciences Executive Keith W. Ward, PhD

 Skye Bioscience Announces Promotion of Tu Diep, MSc to Chief Development Officer SAN DIEGO, CA, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a biopharmaceutical company developing proprietary, synthetic cannabino...
Previous 10 Next 10